414 - REVOLUTIONARY THERAPIES AND THEIR IMPACT ON CV DISEASE

Friday, October 28, 2022

5:30 PM – 5:50 PM EDT

Location: Canada Hall 2 West

Sponsored By

Target Audience: General: All cardiovascular (clinical and research) health professionals

Presenter(s)

Benoit Arsenault

Professor, Laval University
Quebec Heart and Lung Institute
Université Laval
Quebec City, Quebec, Canada
RM

Ruth McPherson

Professor of Medicine and Biochemistry
Univ Ottawa Heart Institute
University of Ottawa
Ottawa, Ontario, Canada
Robert C. Welsh, MD

Zone Clinical Department Head, Cardiac Sciences
Mazankowski Alberta Heart Institute
University of Alberta
Edmonton, Alberta, Canada

Learning Objectives:

At the conclusion of this session, participants will be able to:

discuss the technology of siRNA therapy, with a focus on inclisiran for the management of dyslipidemia; and
describe the role of siRNA therapy in further reducing residual risk and LDL-C in patients with ASCVD.

We are at a new frontier for the management of LDL-C in patients with ASCVD. This session is to further discuss information that was presented during the symposium "The Other Pandemic: How Can we Leverage Revolutionary Technology to Disrupt CV Disease". With inclisiran, a revolutionary therapy based on Nobel Prize-winning RNA interference, we can prevent the synthesis of PCSK9 proteins in hepatocytes, resulting in effective and long-lasting reduction of LDL-C. Join Robert C. Welsh, MD, Ruth McPherson, MD and Benoit Arsenault, PhD, as they discuss and answer your questions around this revolutionary siRNA therapy and how it how it could help to address existing care gaps for patients with ASCVD.